SK Capital Partners has entered into exclusive discussions to acquire a majority stake in SEQENS – a leading integrated developer and manufacturer of Active Pharmaceutical Ingredients, advanced drug intermediates and specialty ingredients.

As part of these discussions, SK Capital also intends to merge Wavelength Pharmaceuticals with SEQENS and create a global leader in the API & CDMO sectors. The deal is expected to close by the end of 2021, subject to the fulfillment of the standard conditions precedent for this type of transaction.

SEQENS headquartered in France, generates an annual turnover of over €1 billion and employs 3000 employees in 19 production sites and 7 R&D centers around the world. A backward-integrated leader in critical consumer care analgesic APIs, offering a broad portfolio of generic APIs and intermediates as well as custom development and manufacturing services across a wide range of pharmaceutical technologies.

Wavelength Pharmaceuticals, a portfolio company of SK Capital Partners, is a customer-focused backward-integrated world-class developer and manufacturer of APIs. Founded in Israel in 1987, with more than 280 customers in 50 countries, Wavelength produces more than 630 metric tons of commercial products every year and offers a full-spectrum of API CDMO services from pre-clinical grams to multi-ton commercial scale.

The proposed merger will create a scaled leader of global industrial footprint and further extend both companies’ broad portfolio of products, services and advanced pharmaceutical technologies, while maintaining and further enhancing their strong culture of quality, regulatory compliance and commitment for exceptional customer service.

Read more

For more information about SEQENS please visit

For more information about SK Capital please visit